Evidence map›Paper›PMID 36795465›Full record

Trial reportJMIR mHealth and uHealth2023

Clinic-Integrated Smartphone App (JomPrEP) to Improve Uptake of HIV Testing and Pre-exposure Prophylaxis Among Men Who Have Sex With Men in Malaysia: Mixed Methods Evaluation of Usability and Acceptability.

Roman Shrestha, Frederick L Altice, Antoine Khati, Iskandar Azwa, Kamal Gautam, Sana Gupta, Patrick Sean Sullivan, Zhao Ni, Adeeba Kamarulzaman, Panyaphon Phiphatkunarnon and 1 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JMIR mHealth and uHealth, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05052411 (Beta Testing of a Smartphone App for HIV Prevention in Malaysian MSM), which is not on this map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05052411 nacompletednot on this map

Beta Testing of a Smartphone App for HIV Prevention in Malaysian MSM

TypeinterventionalSponsorUniversity of ConnecticutRan2022 to 2022Enrolled50ConditionsHIV Prevention ProgramArmsApp usage assessments and analytics
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Roman ShresthaDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, United States.ORCID 0000-0003-4340-3101
Frederick L AlticeAIDS Program, Yale School of Medicine, New Haven, CT, United States.ORCID 0000-0002-7860-693X
Antoine KhatiDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, United States.ORCID 0000-0001-9350-8230
Iskandar AzwaFaculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.ORCID 0000-0003-1977-6709
Kamal GautamDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, United States.ORCID 0000-0002-7121-7421
Sana GuptaDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, United States.ORCID 0000-0002-8595-107X
Patrick Sean SullivanDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.ORCID 0000-0002-7728-0587
Zhao NiYale School of Nursing, West Haven, CT, United States.ORCID 0000-0002-9185-9894
Adeeba KamarulzamanFaculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.ORCID 0000-0002-8074-4450
Panyaphon PhiphatkunarnonLove Foundation, Bangkok, Thailand.ORCID 0000-0001-5804-6106
Jeffrey A WickershamAIDS Program, Yale School of Medicine, New Haven, CT, United States.ORCID 0000-0001-7701-9162
University of Connecticut · USUniversity of Malaya · MYEmory University · USThe Kidney Foundation of Thailand · THYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Development and Testing of a Mobile Application to Enhance HIV Prevention Cascade in Malaysian MSMR33TW011665 · FIC · UNIVERSITY OF CONNECTICUT STORRS · PI SHRESTHA, ROMAN · 2022 to 2024
$885k
Training in MHealth Prevention with MSMK01DA051346 · NIDA · YALE UNIVERSITY · PI SHRESTHA, ROMAN · 2020 to 2024
$862k
Improving HIV testing and PrEP for transgender women through mHealthR21AI157857 · NIAID · YALE UNIVERSITY · PI SHRESTHA, ROMAN, WICKERSHAM, JEFFREY ALLEN · 2021 to 2022
$446k
Development and Testing of a Mobile Application to Enhance HIV Prevention Cascade in Malaysian MSMR21TW011665 · FIC · YALE UNIVERSITY · PI SHRESTHA, ROMAN · 2020 to 2021
$408k
FIC NIH HHS R21 TW011665FIC NIH HHS R33 TW011665NCATS NIH HHS UL1 TR001863NIAID NIH HHS R21 AI157857NIDA NIH HHS K01 DA051346
6 · The paper itself

Abstract

backgroundHIV disproportionately affects men who have sex with men (MSM). In Malaysia, where stigma and discrimination toward MSM are high, including in health care settings, mobile health (mHealth) platforms have the potential to open new frontiers in HIV prevention.

objectiveWe developed an innovative, clinic-integrated smartphone app called JomPrEP, which provides a virtual platform for Malaysian MSM to engage in HIV prevention services. In collaboration with the local clinics in Malaysia, JomPrEP offers a range of HIV prevention (ie, HIV testing and pre-exposure prophylaxis [PrEP]) and other support services (eg, referral to mental health support) without having to interface face to face with clinicians. This study evaluated the usability and acceptability of JomPrEP to deliver HIV prevention services for MSM in Malaysia.

methodsIn total, 50 PrEP-naive MSM without HIV in Greater Kuala Lumpur, Malaysia, were recruited between March and April 2022. Participants used JomPrEP for a month and completed a postuse survey. The usability of the app and its features were assessed using self-report and objective measures (eg, app analytics, clinic dashboard). Acceptability was evaluated using the System Usability Scale (SUS).

resultsThe participants' mean age was 27.9 (SD 5.3) years. Participants used JomPrEP for an average of 8 (SD 5.0) times during 30 days of testing, with each session lasting an average of 28 (SD 38.9) minutes. Of the 50 participants, 42 (84%) ordered an HIV self-testing (HIVST) kit using the app, of whom 18 (42%) ordered an HIVST more than once. Almost all participants (46/50, 92%) initiated PrEP using the app (same-day PrEP initiation: 30/46, 65%); of these, 16/46 (35%) participants chose PrEP e-consultation via the app (vs in-person consultation). Regarding PrEP dispensing, 18/46 (39%) participants chose to receive their PrEP via mail delivery (vs pharmacy pickup). The app was rated as having high acceptability with a mean score of 73.8 (SD 10.1) on the SUS.

conclusionsJomPrEP was found to be a highly feasible and acceptable tool for MSM in Malaysia to access HIV prevention services quickly and conveniently. A broader, randomized controlled trial is warranted to evaluate its efficacy on HIV prevention outcomes among MSM in Malaysia.

trial registrationClinicalTrials.gov NCT05052411; https://clinicaltrials.gov/ct2/show/NCT05052411. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.2196/43318.

Indexed as

HIV InfectionsMobile ApplicationsPre-Exposure ProphylaxisSexual and Gender MinoritiesAdultHIV TestingHomosexuality, MaleHumansMalaysiaMaleacceptabilitygayHIVHIV preventionhomosexualMalaysiamen who have sex with menmHealthmobile healthmobile phoneMSMpre-exposure prophylaxispreventionsexual minorityusability

Identifiers

PMID36795465
PMCPMC9982718
OpenAlexW4321002251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.